ELCC2019
size: 202.59 MB
|- Where nursing fits.pdf - 848.00 kB
|- What is the role of surgery for stage III patients in the I-O era.pdf - 1.40 MB
|- What is the biological rationale for combining chemotherapy with immune checkpoint inhibitors.pdf - 4.80 MB
|- What caregivers do for patients affected by cancer.pdf - 383.00 kB
|- What can LuCE achieve in terms of lobbying.pdf - 1.30 MB
|- Treatment options from the medical oncologist’s perspective.pdf - 1.50 MB
|- Treatment of localised disease.pdf - 3.00 MB
|- Treatment Duration of Brigatinib in Patients Enrolled in the International Expanded Access Program (EAP).pdf - 494.00 kB
|- Treatment algorithms for oligoprogressive and oligometastatic disease.pdf - 2.10 MB
|- TMB trumps PD-L1 as predictive biomarker for immuno-oncology therapy.pdf - 3.20 MB
|- TMB as predictor of immuno-oncology therapy.pdf - 2.40 MB
|- The role of the pathologist Multiple primaries vs metastatic disease.pdf - 4.40 MB
|- The role of IASLC in helping to implement personalised medicine.pdf - 3.00 MB
|- The role of brain irradiation.pdf - 1.30 MB
|- The respiratory and medical oncology perspective.pdf - 1.20 MB
|- The radiation oncology perspective.pdf - 2.30 MB
|- The pathologist’s point of view.pdf - 3.20 MB
|- The experience and impact of cancer caregiving through the cancer continuum.pdf - 476.00 kB
|- The effect of prophylactic cranial irradiation (PCI) for young stage III NSCLC patients.pdf - 419.00 kB
|- Targeted therapy beyond EGFR, ALK and ROS1.pdf - 7.30 MB
|- Synchronous and metachronous primary tumours.pdf - 1.20 MB
|- Surgical decision To operate or not to operate.pdf - 3.50 MB
|- Supporting lung cancer survivors Living with and beyond lung cancer.pdf - 1.10 MB
|- Supporting lung cancer patients through virtual environments.pdf - 1.50 MB
|- STELLAR – Final updated results of a phase 2 trial of TTFields with chemotherapy for unresectable malignant pleural mesothelioma.pdf - 402.00 kB
|- should upfront ngs be our new standard of.pdf - 2.50 MB
|- Sequencing systemic therapy with driver mutations.pdf - 2.00 MB
|- Sequencing of I-O therapies.pdf - 1.60 MB
|- SCLC The surgeon´s point of view.pdf - 2.50 MB
|- SCLC The radiation oncologist’s point of view.pdf - 1.90 MB
|- SCLC The medical oncologist’s point of view.pdf - 4.50 MB
|- Safety and Efficacy of Pembrolizumab (Pembro) Monotherapy in Elderly Patients (Pts) With PD-L1–positive Advanced NSCLC.pdf - 1.50 MB
|- Role of radiotherapy in oligometastatic I-O progression.pdf - 446.00 kB
|- Robotic assisted lung resection for locally advanced lung cancer.pdf - 2.30 MB
|- Reflections from the French experience.pdf - 3.00 MB
|- Recommendation on second-line treatment according to first-line choice.pdf - 4.20 MB
|- RECaN What this project has taught us about advanced roles.pdf - 1.70 MB
|- Radiogenomic signatures of NSCLC brain metastases.pdf - 1.10 MB
|- Quality of life after radical treatment for lung cancer.pdf - 4.00 MB
|- Progression on PD1 PD-L1 inhibitors What is in the pipeline.pdf - 3.40 MB
|- Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC).pdf - 327.00 kB
|- Predictive diagnostics and treatment algorithms.pdf - 4.50 MB
|- Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small-cell lung cancer patients with primary resistan.pdf - 683.00 kB
|- Potential biomarkers for MPM in asbestos-exposed subjects.pdf - 4.10 MB
|- Phase 1 study of gefitinib (G) + durvalumab (D) .pdf - 634.00 kB
|- PD-L1 is superior to TMB as predictive biomarker for immuno-oncology therapy.pdf - 3.60 MB
|- Patient’s experience of the integrated model of care.pdf - 956.00 kB
|- Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, Stage III NSCLC (PACIFIC).pdf - 555.00 kB
|- Overcoming resistance to immune checkpoint inhibitors.pdf - 7.50 MB
|- Oligometastatic NSCLC.pdf - 3.00 MB
|- Novel targets, new therapeutic strategies and future perspectives.pdf - 1.60 MB
|- Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung can.pdf - 472.00 kB
|- My patient needs surgery upfront followed by adjuvant treatment.pdf - 2.70 MB
|- My patient needs neoadjuivant treatment followed by surgery.pdf - 1.20 MB
|- Molecular targets and therapies for SCLC.pdf - 2.90 MB
|- Mentor guided discussion Role of radiotherapy in oligometastatic I-O progression.pdf - 714.00 kB
|- Mentor guided discussion ALK inhibitors best sequence.pdf - 1.90 MB
|- Management of pulmonary toxicities Clinical case.pdf - 4.00 MB
|- Management of I-O toxicities An introduction.pdf - 1.40 MB
|- Management of GI toxicities Clinical case.pdf - 597.00 kB
|- Management of endocrine toxicities Clinical case.pdf - 1.20 MB
|- Management of cough in patients with LC.pdf - 1.40 MB
|- Local treatment in oligoprogressive disease.pdf - 1.60 MB
|- Lobar vs. sublobar resections for stage I NSCLC.pdf - 1.60 MB
|- Is palliative care under threat for stigma.pdf - 168.00 kB
|- Invited Discussant 84O, 104O and 105O.pdf - 1.70 MB
|- Invited Discussant 83O, LBA2 and LBA4.pdf - 2.20 MB
|- Invited Discussant 68O and 69O.pdf - 1.80 MB
|- Invited Discussant 21O and 108O.pdf - 1.80 MB
|- Invited Discussant 109O, 55O and 110O.pdf - 4.00 MB
|- Intratumoural I-O A niche therapy.pdf - 3.30 MB
|- Integrating early palliative care to oncology care.pdf - 742.00 kB
|- IMpower150 an exploratory analysis of efficacy outcomes in patients with EGFR mutations.pdf - 1.00 MB
|- Importance of access to innovative treatments and their impact on patient reported outcomes.pdf - 1.00 MB
|- Impact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, Stage III NSCLC from PACIFIC.pdf - 389.00 kB
|- Impact of MET variants on PD-L1 expression in Pleomorphic Lung Carcinoma.pdf - 673.00 kB
|- Immunotherapy in oncogenic addicted NSCLC.pdf - 3.40 MB
|- Immune targets and therapies for SCLC.pdf - 4.20 MB
|- I-O until PD.pdf - 1.60 MB
|- I-O monotherapy.pdf - 1.70 MB
|- How to define it How to treat it.pdf - 1.50 MB
|- How can ESMO help to implement personalised treatment in clinical practice.pdf - 3.20 MB
|- How accurate are we in measuring quality of life.pdf - 1.50 MB
|- First-line immunotherapy options for patients without an oncogene driver.pdf - 3.40 MB
|- Final Analysis of the Phase 3 KEYNOTE-042 Study Pembrolizumab (Pembro) Versus Platinum-Based Chemotherapy (Chemo).pdf - 2.20 MB
|- Facts and myths of liquid biopsy.pdf - 3.10 MB
|- Experiences from the German Network Genomic Medicine.pdf - 2.40 MB
|- Evaluation and challenges of advanced practice lung cancer nurses in current context.pdf - 663.00 kB
|- Epidemiology and asbestos ban European picture.pdf - 2.80 MB
|- EPAC-Lung Pooled Analysis of Circulating Tumor Cells in Advanced Non-Small Cell Lung Cancer.pdf - 678.00 kB
|- Entrectinib in NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).pdf - 528.00 kB
|- Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).pdf - 827.00 kB
|- elcc 2019 mystic subsequent tx presentation final.pdf - 671.00 kB
|- EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases.pdf - 345.00 kB
|- Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs).pdf - 299.00 kB
|- Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patien.pdf - 906.00 kB
|- Early stage NSCLC.pdf - 1.80 MB
|- Early stage lung cancer The importance of co-morbidity.pdf - 1.60 MB
|- Early stage lung cancer Progress in TNM.pdf - 1.90 MB
|- Do we need a molecular board in our hospital.pdf - 4.10 MB